Nuria Chic

Grup de recerca

Genòmica translacional i teràpies dirigides en tumors sòlids Pre-doctoral researcher (R1)

chic@clinic.cat 0000-0001-9736-6276

Publicacions destacades

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer

Autors:
Chic, N; Prat, A; Di Cosimo, S; Saura, C; Luen, SJ;

(...)

Hilbers, F; Wang, YB; de Azambuja, E; Láng, I; Huober, J.

Referència: Journal Of The National Cancer Institute 2022.
Gene expression profiles of breast cancer metastasis according to organ site

Autors:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Referència: Molecular Oncology 2022.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Autors:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Referència: Ebiomedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Autors:
Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

(...)

Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

Referència: Journal Of Clinical Oncology 2021.
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Autors:
Buus, R; Schuster, EF; Xiao, H; Dowsett, M; Haynes, BP;

(...)

Cuzick, J; Paré, L; Seguí, E; Chic, N; Prat, A.

Referència: Npj Breast Cancer 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Autors:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Referència: Npj Breast Cancer 2021.
Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Autors:
Chic, Nuria; Luen, Stephen; Nuciforo, Paolo; Salgado, Roberto; Fumagalli, Debora;

(...)

Di Cosimo, Serena; Saura, Cristina; Huober, Jens; Prat, Aleix; Loi, Sherene;.

Referència: Cancer Research 2021.
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Autors:
Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A; Frassoldati, Antonio;

(...)

Pare, Laia; Chic, Nuria; D'Amico, Roberto; Prat, Aleix; Conte, Pierfranco.

Referència: Clinical Cancer Research 2020.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Autors:
Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

(...)

Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

Referència: Lancet Oncology 2020.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Autors:
Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;

(...)

Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.

Referència: Breast Cancer Research 2020.

Projectes destacats

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Durada: 01/02/2020
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Durada: 02/12/2019

Nuria Chic

Grup de recerca

Publicacions destacades

Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Projectes destacats

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Subscriu-te a la Newsletter del Clínic